Tamtam Try Tamtam free
Orthofix logo

Orthofix account plan

Leading global spine and orthopedics

At a glance

Orthofix (NASDAQ: OFIX) sells spinal implants, bone growth stimulators and limb reconstruction systems; FY2025 net sales $822.3 million.

Orthofix Medical Inc., headquartered in Lewisville, Texas and founded in Verona, Italy in 1980, sells spinal implants, bone growth stimulation devices, biologics, limb reconstruction systems and the 7D FLASH Navigation System to hospitals, ASCs and purchasing organizations in more than 60 countries. It merged with SeaSpine in January 2023 and trades on NASDAQ as OFIX. FY2025 net sales were $822.3 million (+2.9% reported), with a gross margin of 68.8% and a net loss of $92.2 million; U.S. net sales were $684.1 million. It had 1,605 employees at the end of 2025, 1,222 of them in the U.S., and manufactures in the U.S., Canada, Germany, Spain, China and Italy. Massimo Calafiore is President and CEO.

Business units

Strategic priorities

Fix U.S. Spine execution
Concentrate on core distributors, which generate around 80% of U.S. spinal implant revenue, accelerate exits from weaker relationships and redeploy instrument sets to them.
Simplify the portfolio and align costs
Focus inventory, capital and commercial support on differentiated platforms such as VIRATA, whose full market launch for open procedures is expected later in Q4 2026, after discontinuing the M6 artificial discs in February 2025.
Grow Limb Reconstruction in the U.S.
Ramp TrueLok Elevate and Fitbone, pursue diabetic foot ulcers as a potential new indication (IDE submitted to the FDA) and an automated TrueLok Elevate (510(k) submitted in September 2026).
Integrate implants and biologics with 7D
Move 7D FLASH from capital sales to an earn-out model tied to implant and biologics purchase commitments; earn-out placements were 30% above 2024 and 7D received two 510(k) clearances in Q3 2026.
Stabilize Biologics with clinical evidence
Invest in clinical evidence for OsteoCove and a registry for OsteoStrand Plus after double-digit declines in 2025; Biologics was about flat year over year in Q2 2026.
Financial discipline and long-range plan
Long-range plan targets were kept but pushed from 2027 to 2028; management targets positive free cash flow and stays open to tuck-in acquisitions.

Latest results

In Q3 2026 (quarter ended September 30) net sales were $207.9 million, +1.1% reported and +2.2% pro forma excluding M6, with a net loss of $6.1 million and adjusted EBITDA of $26.0 million (12.5% of pro forma sales). Therapeutic Solutions grew 4.5% and Limb Reconstruction 8.5%, while Spinal Implants, Biologics and Enabling Technologies fell 1.1% and U.S. Spine Fixation fell 5%. SG&A dropped 15.4% to $125.3 million on $21.2 million lower legal costs. Over nine months net sales were $615.5 million (+2.2%) and free cash flow was $(61.3) million. Full-year 2026 guidance was cut to $825-830 million pro forma net sales and $86-88 million adjusted EBITDA.

Investments and deals

Oxford Finance credit agreement
A $275.0 million secured credit agreement: $160.0 million Initial Term Loan, $65.0 million Term B Loan drawn January 15, 2026, and a $50.0 million Term C at the lender's discretion; $225.0 million was outstanding at September 30, 2026.
European MDR distributor arrangement
One of the largest European distributors is funding MDR certification for spine products, adding about $15 million of 2026 sales (mostly Q4) and creating an approximately $22 million headwind in 2027.
Instrument sets and capex
Nine-month 2026 capex rose to $37.8 million from $23.7 million, including instrument sets ahead of the VIRATA launch.
Settlement of executive litigation
Orthofix paid $14.8 million to its former CEO Keith Valentine in April 2026, and former executives Keran and Bostjancic settled for $4.25 million each.

Challenges and risks

Supplier delays and instrument-set constraints
Unplanned supplier delays, concentrated in instrument manufacturing and some interbody product lines, constrained inventory and instrument sets in U.S. Spine in Q3 2026.
Underperforming smaller distributors
Smaller spine distributors kept underperforming, and growth among the Top 30 distributors slowed to the mid-single digits in Q3 2026.
Bone growth stimulator reclassification
The FDA reclassified bone growth stimulators from Class III to Class II, which could let competitors enter more easily and lead to pricing pressure.
Cash generation
Free cash flow was $(1.3) million in 2025 and $(61.3) million over the first nine months of 2026, with inventory turns down to 1.3x.
Pricing pressure and supplier dependence
GPO price concessions, dependence on independent distributors and on single-source suppliers such as MTF for key allografts.

What leadership says

“We are concentrating resources behind our strongest partners and the highest value technology, simplifying the portfolio and aligning costs with a more focused business.”

Massimo Calafiore, President and Chief Executive Officer · Q3 2026 earnings call, November 9, 2026

“Our priorities are clear: improve U.S. Spine execution, stabilize Biologics, build on the strength of limb reconstruction, Therapeutic Solutions and maintain financial discipline.”

Massimo Calafiore, President and Chief Executive Officer · Q3 2026 earnings call, November 9, 2026

“Our objective is not growth at any cost. It is durable, profitable growth supported by better commercial productivity, disciplined investment, and stronger business fundamentals.”

Massimo Calafiore, President and Chief Executive Officer · Q2 2026 earnings call, August 5, 2026

“Over 75% of our business is with our top 30 distributors. And if you go back to 2024, that was less than 50%.”

Julie Andrews, Chief Financial Officer · Canaccord Genuity Musculoskeletal Conference, March 2, 2026

Where a supplier can help

Instrument and component manufacturing capacity
Tied to the supplier-delay challenge: contract manufacturers of surgical instruments and interbody components could reduce the constraints that held back U.S. Spine.
Asset and inventory utilization tools
Tied to the redeployment of instrument sets and low inventory turns: consignment tracking, set logistics and inventory analytics help core distributors turn assets faster.
Clinical evidence and regulatory services
Tied to the Biologics evidence priority, the diabetic foot ulcer IDE and the European MDR work: CROs, registries and regulatory consultants.
U.S. commercial build-out for Limb Reconstruction
Tied to the U.S. Limb Reconstruction priority: sales enablement, surgeon education and distributor recruitment for a market the company calls greenfield.
Cost alignment and cash discipline
Tied to the cost-alignment priority and negative free cash flow: procurement, working-capital and operational efficiency services.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Orthofix?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Orthofix

What does Orthofix do?

Orthofix is a medical technology company in Lewisville, Texas that sells spinal implants, bone growth stimulators, biologics, limb reconstruction systems and the 7D FLASH Navigation System in more than 60 countries.

What is Orthofix's revenue?

FY2025 net sales were $822.3 million (+2.9% reported) with a net loss of $92.2 million. For 2026 the company guides to $825-830 million of pro forma net sales.

How many employees does Orthofix have?

1,605 employees at December 31, 2025: 1,222 in the U.S. and 383 outside, including 247 in Italy.

Who leads Orthofix?

Massimo Calafiore is President and CEO and Julie Andrews is CFO.

What is Orthofix's strategy?

Improve U.S. Spine execution by concentrating on core distributors, simplify the portfolio around platforms such as VIRATA and 7D, stabilize Biologics, grow Limb Reconstruction and Therapeutic Solutions, and keep financial discipline.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)